Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Blood (2023) 142 (Supplement 1): 160.

https://doi.org/10.1182/blood-2023-184445

Published: 2023

Journal Articles

Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Maximilian Alexander Röhnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Martin Bornhaeuser, Uta Oelschlägel, Malte von Bonin

Blood (2022) 140 (Supplement 1): 11824–11826.

https://doi.org/10.1182/blood-2022-165260

Published: 2022

Journal Articles

Gut Microbiome, Metabolome and Immune Changes in Myelodysplastic Syndromes

Ekaterina Balaian, Nikolai Karcher, Katja Sockel, Uta Oelschlägel, Alexander Funk, Manja Wobus, Maria Uhlig, Matthias W. Groß, Sebastian Zeissig, Martin Bornhaeuser, Triantafyllos Chavakis, Georg Zeller

Blood (2022) 140 (Supplement 1): 12301–12302.

https://doi.org/10.1182/blood-2022-165481

Published: 2022

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Blood (2022) 140 (Supplement 1): 3327–3328.

https://doi.org/10.1182/blood-2022-159897

Published: 2022

Journal Articles

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Maximilian Alexander A Rohnert, Malte von Bonin, Michael Kramer, Philipp Ensel, Nadja Holtschke, Christoph Rollig, MD MSC, Martin Bornhäuser, MD, Veit Buecklein, MD, Marion Subklewe, MD, Stefan W Krause, Simon Voelkl, Tobias Berg, Michael A Rieger, Cornelia Brendel, Jörg Hoffmann, Nicole Hofmeister-Mielke, Richard F. Schlenk, Sylvie D Freeman, Uta Oelschlägel

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-138683

Published: 2020

Journal Articles

Differential Distribution of Clonal Hematopoiesis in Flow-Sorted Subpopulations of Patients with Myelodysplastic Syndromes (MDS)

Maximilian Alexander Röhnert, Uwe Platzbecker, MD, Uta Oelschlägel, PhD, Christian Thiede, MD, Gerhard Ehninger, MD, Martin Bornhäuser, MD, Brigitte Mohr, PhD

Blood (2014) 124 (21): 4626.

https://doi.org/10.1182/blood.V124.21.4626.4626

Published: 2014

Journal Articles

CD97 Expression in Acute Myeloid Leukemia Is Associated with FLT3-ITD Mutation Status

Manja Wobus, PhD, Martin Bornhäuser, MD, Claudia Ortlepp, PhD, Angela Jacobi, PhD, Gerhard Ehninger, MD, Christian Thiede, MD, Uta Oelschlägel, PhD

Blood (2014) 124 (21): 1001.

https://doi.org/10.1182/blood.V124.21.1001.1001

Published: 2014

Journal Articles

Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis

Friedrich Stölzel, MD, Brigitte Mohr, PhD, Michael Kramer, PhD, Christoph Röllig, MD, Tilmann Bochtler, MD, Alwin Krämer, MD, Uta Oelschlägel, PhD, Jan Moritz Middeke, MD, Uwe Platzbecker, MD, PhD, Markus Schaich, MD, Johannes Schetelig, MD, Gerhard Ehninger, MD, Martin Bornhäuser, MD

Blood (2013) 122 (21): 489.

https://doi.org/10.1182/blood.V122.21.489.489

Published: 2013

Journal Articles

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

Uwe Platzbecker, MD, Ulrich Schuler, Martin Bornhäuser, Michael Kramer, Markus Schaich, MD, Uta Oelschlagel, Brigitte Mohr, Mathias Hänel, Hannes Wandt, Thomas Wagner, Hermann Einsele, Stefan W. Krause, MD, Heinrich Bodenstein, Walter E. Aulitzky, Norbert Schmitz, Anthony D. Ho, Gerhard Ehninger, MD, Christoph Röllig, MD

Blood (2011) 118 (21): 765.

https://doi.org/10.1182/blood.V118.21.765.765

Published: 2011

Journal Articles

CD34 + cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice

Blood (2010) 116 (19): 3907–3922.

https://doi.org/10.1182/blood-2009-08-238899

Published: 2010

Includes: Supplemental data

Journal Articles

Differences in Reconstitution of NK-Cell Subsets and Expression of Effector Molecules after HLA-Identical and Haploidentical Allogeneic Stem Cell Transplantation in Patients with AML.

Uwe Platzbecker, MD, Astrid Schulze, Uta Oelschlagel, MD, Holger Schirutschke, Marc Schmitz, MD, Gerhard Ehninger, MD, Martin Bornhauser, MD

Blood (2005) 106 (11): 1411.

https://doi.org/10.1182/blood.V106.11.1411.1411

Published: 2005

NARROW

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Gut Microbiome, Metabolome and Immune Changes in Myelodysplastic Syndromes

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Differential Distribution of Clonal Hematopoiesis in Flow-Sorted Subpopulations of Patients with Myelodysplastic Syndromes (MDS)

CD97 Expression in Acute Myeloid Leukemia Is Associated with FLT3-ITD Mutation Status

Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis

Two Cycles of Risk-Adapted Consolidation Leads to a Favorable Long-Term Prognosis in Patients with Acute Promyelocytic Leukemia After Standard AIDA Induction: Results From 141 Patients Treated in the SAL-AIDA-2000 Trial

CD34 + cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice

Differences in Reconstitution of NK-Cell Subsets and Expression of Effector Molecules after HLA-Identical and Haploidentical Allogeneic Stem Cell Transplantation in Patients with AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only